3 High-Risk/High-Reward Stocks With 100%+ Upside Potential, According to Analysts
Several high-risk, high-reward stocks come from companies that operate in industries where conditions change quickly. As a result, they carry great...
Aclaris Therapeutics Inc. (ACRS)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | RA Capital Management Peter Kolchinsky | 12,723,026 | $67,304,808 | +87% | 0.58% |
| 2. | Deep Track Capital David Kroin | 9,345,000 | $49,435,050 | 0.72% | |
| 3. | Vivo Capital Albert Cha And Frank Kung | 6,694,637 | $35,414,630 | +1% | 3.23% |
| 4. | Rock Springs Capital Management Kris Jenner, Gordon Bussard, Graham Mcphail | 4,330,532 | $22,908,514 | -4% | 1.12% |
| 5. | Adage Capital Management Phill Gross And Robert Atchinson | 4,071,000 | $21,535,590 | +6% | 0.03% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $2.25 | 666,666 | $1,499,998.50 | 710,030 | 2024-11-19 | Filing | |
| $1.24 | 206,025 | $256,356.91 | 14,250,000 | 2024-08-05 | Filing | |
| $1.29 | 167,544 | $216,399.83 | 14,043,975 | 2024-08-02 | Filing | |
| $1.33 | 100,000 | $132,640.00 | 13,876,421 | 2024-07-31 | Filing | |
| $1.30 | 173,730 | $226,370.19 | 13,776,421 | 2024-07-30 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $4.53 | 300,000 | $1,359,000.00 | 13,950,000 | 2026-04-23 | Filing | |
| $5.08 | 6,000 | $30,460.20 | 129,724 | 2023-10-23 | Filing | |
| $7.32 | 6,000 | $43,894.80 | 135,724 | 2023-08-21 | Filing | |
| $10.28 | 6,000 | $61,662.60 | 141,724 | 2023-06-20 | Filing | |
| $12.63 | 30,240 | $382,070.30 | 1,273,202 | 2023-03-03 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 154,554 | $812,954 | 0% | |
| 2. | 18,790 | $98,835 | 0% | |
| 3. | 17,782 | $93,534 | 0.01% | |
| 4. | 15,759 | $82,892 | 0% | |
| 5. | 3,657 | $19,236 | 0% |
News See All
Investors' Stock Portfolio: Top 10 Penny Stocks To Buy
In this article, we will discuss Investors' Stock Portfolio: Top 10 Penny Stocks To Buy. Risk appetite, driven by artificial intelligence fervor, continues to drive sentiment in US equity markets.
Acadian Increases Stake in Aclaris Therapeutics, Inc. (ACRS) as Phase 2a Data Gains Spotlight
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) is among the best fundamentally strong penny stocks to buy right now.
12 Best Fundamentally Strong Penny Stocks to Buy Right Now
In this article, we will take a look at some of the best fundamentally strong penny stocks to buy right now.
Aclaris Therapeutics Reports Positive Phase 2a Clinical Trial Results for ATI-2138
Aclaris Therapeutics Inc. (NASDAQ:ACRS) is one of the most promising penny stocks under $5.
13 Most Promising Penny Stocks Under $5
On August 12, Jill Carey Hall, BofA Securities head of US small and mid-cap strategy, joined 'The Exchange' on CNBC to discuss the outlook for small caps, amidst their underperformance.
Aclaris Therapeutics Begins Phase 1 Clinical Trial for Bispecific Antibody ATI-052 Targeting Inflammatory Diseases
Aclaris Therapeutics Inc. (NASDAQ:ACRS) is one of the best low priced pharma stocks to buy now.
13 Best Low Priced Pharma Stocks to Buy Now
On July 9, Afsaneh Beschloss, RockCreek Group founder & CEO, joined 'Closing Bell Overtime' on CNBC to talk about the latest round of tariff threats.
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Q1 2024 Earnings Call Transcript
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Q1 2024 Earnings Call Transcript May 7, 2024 Aclaris Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.23835, expectations were $-0.28.
5 Cheap Small-Cap Stocks to Buy Before the Next Breakout
In this piece, we will take a look at five cheap small cap stocks to buy before the next breakout.